Yhhu4488, a novel GPR40 agonist, promotes GLP-1 secretion and exerts anti-diabetic effect in rodent models

Biochemical and Biophysical Research Communications

Volumn 466, Issue 4, 2015, Pages 740-747

  Guo, Dan Yang ^a   Li, De Wen ^a   Ning, Meng Meng ^a   Dang, Xiang Yu ^a   Zhang, Li Na ^a   Zeng, Li Min ^a   Hu, You Hong ^a   Leng, Ying ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Glucagon like peptide 1; GPR40; Insulin; Type 2 diabetes mellitus; Yhhu4488

Indexed keywords

ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; UNCLASSIFIED DRUG; YHHU 4488; FFAR1 PROTEIN, HUMAN; G PROTEIN COUPLED RECEPTOR; G-PROTEIN-COUPLED RECEPTOR 40, RAT; GPR40 PROTEIN, MOUSE; PHENYLPROPIONIC ACID DERIVATIVE; PYRIDINE DERIVATIVE; YHHU4488;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CELL FUNCTION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DB/DB MOUSE; DRUG EFFECT; DRUG POTENCY; EC50; EXTRACELLULAR CALCIUM; FEMALE; FETAL RAT INTESTINAL CELL; FETUS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; HEK293 CELL LINE; HUMAN; IN VIVO STUDY; INTESTINE CELL; INVESTIGATIVE PROCEDURES; LIPID HOMEOSTASIS; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; AGONISTS; ANIMAL; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE TOLERANCE TEST; MUTANT MOUSE STRAIN; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; PREGNANCY; SECRETION (PROCESS);

ANIMALS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MALE; MICE; MICE, MUTANT STRAINS; PHENYLPROPIONATES; PREGNANCY; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84943255497     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.09.130     Document Type: Article

References (23)

1. F.M. Ashcroft, and P. Rorsman Diabetes mellitus and the β cell: the last ten years Cell 148 2012 1160 1171
2. E. Bonora Protection of pancreatic beta-cells: is it feasible? Nutr. Metab. Cardiovasc. Dis. 18 2008 74 83
3. H. Ledford Diabetes drugs ride a bumpy road Nature 504 2013 198
4. A.D. Mancini, and V. Poitout The fatty acid receptor FFA1/GPR40 a decade later: how much do we know? Trends Endocrinol. Metab. 24 2013 398 407
5. C.F. Burant Activation of GPR40 as a therapeutic target for the treatment of type 2 diabetes Diabetes Care 36 2013 175 179
6. H. Kristinsson, D.M. Smith, P. Bergsten, and E. Sargsyan FFAR1 is involved in both the acute and chronic effects of palmitate on insulin secretion Endocrinology 154 2013 4078 4088
7. P. Steneberg, N. Rubins, R. Bartoov-Shifman, M.D. Walker, and H. Edlund The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse Cell Metab. 1 2005 245 258
8. K. Nagasumi, R. Esaki, K. Iwachidow, Y. Yasuhara, K. Ogi, H. Tanaka, and et al. Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice Diabetes 58 2009 1067 1076
9. E. Defossa, and M. Wagner Recent developments in the discovery of FFA1 receptor agonists as novel oral treatment for type 2 diabetes mellitus Bioorg. Med. Chem. Lett. 24 2014 2991 3000
10. S. Edfalk, P. Steneberg, and H. Edlund Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion Diabetes 57 2008 2280 2287
11. Y.M. Cho, Y. Fujita, and T.J. Kieffer Glucagon-like peptide-1: glucose homeostasis and beyond Annu. Rev. Physiol. 76 2014 535 559
12. X. Liu, L. Zhang, Y. Feng, L. Zhang, H. Qu, G. Cao, and et al. Acute and chronic administration of SHR117887, a novel and specific dipeptidyl peptidase-4 inhibitor, improves metabolic control in diabetic rodent models Acta Pharmacol. Sin. 33 2012 1013 1022
13. Y. Itoh, Y. Kawamata, M. Harada, M. Kobayashi, R. Fujii, S. Fukusumi, and et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40 Nature 422 2003 173 176
14. C.P. Briscoe, M. Tadayyon, J.L. Andrews, W.G. Benson, J.K. Chambers, M.M. Eilert, and et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids J. Biol. Chem. 278 2003 11303 11311
15. J. Luo, G. Swaminath, S.P. Brown, J. Zhang, Q. Guo, M. Chen, and et al. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents PLoS One 7 2012 1 12
16. C.F. Burant, P. Viswanathan, J. Marcinak, C. Cao, M. Vakilynejad, B. Xie, and et al. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial Lancet 379 2012 1403 1411
17. D.C.H. Lin, J. Zhang, R. Zhuang, F. Li, K. Nguyen, M. Chen, and et al. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents PLoS One 6 2011
18. N. Negoro, S. Sasaki, S. Mikami, M. Ito, M. Suzuki, Y. Tsujihata, and et al. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist ACS Med. Chem. Lett. 1 2010 290 294
19. F. Reimann, P.S. Ward, and F.M. Gribble Signaling mechanisms underlying the release of glucagon-like peptide 1 Diabetes 55 2006 S78 S85
20. 2+/calmodulin-dependent kinase II activation Biochem. Biophys. Res. Commun. 435 2013 165 170
21. N. Gowda, A. Dandu, J. Singh, S. Biswas, V. Raghav, M.N. Lakshmi, and et al. Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats BMC Pharmacol. Toxicol. 14 2013 28
22. J. Buteau, S. Foisy, E. Joly, and M. Prentki Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor Diabetes 52 2003 124 132
23. L. Farilla, A. Bulotta, B. Hirshberg, S. Li Calzi, N. Khoury, H. Noushmehr, and et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets Endocrinology 144 2003 5149 5158